| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We examined the effect of multi-kinase inhibitor Sunitinib on MEN2A-RET thyroid medullary carcinoma cells, and Sunitinib presented remarkable inhibition of cell growth, migration and phosphorylation of down stream signaling molecules. Oral administration of Sunitinib to MoMuLV/RET-MEN2A mice exhibited significant tumor regression suggesting the promising effect of Sunitinib on MEN2A patients. LC/MS analysis on thyroid carcinoma tissue of MoMuLV/RET-MEN2A mice presented various interesting phosphotyrosine-binding proteins, and further analysis is required to elucidate the significance of these proteins in thyroid carcinogenesis.
|
